Grupo de Investigación en Fisiopatología Cardiovascular
CTS237
Hospital Universitario San Cecilio
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (27)
2022
-
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
JHEP Reports, Vol. 4, Núm. 5
-
HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION
Actas espanolas de psiquiatria, Vol. 50, Núm. 2, pp. 120-121
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2021
-
Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?
International Journal of STD and AIDS, Vol. 32, Núm. 13, pp. 1257-1260
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810
-
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy
Journal of Viral Hepatitis, Vol. 28, Núm. 6, pp. 878-886
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2020
-
Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 3, pp. 127-131
-
Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32
2019
-
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Journal of Hepatology
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
HIV Medicine, Vol. 20, Núm. 6, pp. 359-367
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
-
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51
-
The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641
2018
-
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice
HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30
-
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLoS ONE, Vol. 13, Núm. 7
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
-
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
PLoS ONE, Vol. 11, Núm. 2
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5